Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

Eli Lilly LLY has experienced significant growth in the past few years, particularly driven by the success of its popular ...

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

According to a Motilal Oswal report, real estate giants will sustain growth through new launches with a 12% CAGR from FY25-27. The sector's prospects remain robust, though regulatory hold-ups and ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will ...